# M3T01

Source: https://onco.cc/drugs/m3t01/  
OnCo record `m3t01` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

M3T01 is an antibody from Gamma Biotherapeutics that blocks Fas ligand to protect cancer-fighting T cells, in a phase 1 trial in advanced solid tumours.

## Summary

M3T01 is the lead programme of Gamma Biotherapeutics, a monoclonal antibody against Fas ligand. It is being tested as monotherapy and with pembrolizumab and other systemic therapies in a phase 1 trial in advanced solid tumours, NCT06719362, sponsored by Providence Health & Services and recruiting since June 2025. The National Cancer Institute funds its clinical development through an SBIR award (1R44CA310416-01).

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline
- Code: M3T01
- Modality: Monoclonal antibody
- Mechanism: Neutralises Fas ligand (FasL), which tumours produce and which drives apoptosis of activated T cells, so that T cells survive to enter and attack the tumour.

## Sources

- ClinicalTrials.gov: NCT06719362: https://clinicaltrials.gov/study/NCT06719362
- NIH RePORTER: 1R44CA310416-01: https://reporter.nih.gov/project-details/11315901

## Connected records

- companies: [Gamma Biotherapeutics](https://onco.cc/companies/gamma-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/m3t01.json